Congress moves to silence Big Pharma's direct-to-consumer drug ads for 3 years

What it does

This bill amends federal drug law to ban direct-to-consumer advertising (including on social media) for newly approved drugs for the first 3 years after FDA approval. After that period, the FDA can continue to prohibit advertising if the drug shows significant safety problems. The bill allows the FDA to waive the 3-year ban during year 3 if advertising would benefit public health. The restriction applies to drugs approved starting roughly one year before the bill's enactment.

Why we flagged it

The bill's operative mechanism is a direct restriction on pharmaceutical marketing to consumers, paired with FDA authority to extend or impose advertising bans based on safety data. This is a straightforward regulatory constraint on industry marketing practices, not a subsidy, immunity grant, or deregulation.

What the text implies

• The 3-year moratorium may delay patient awareness of new treatment options, potentially affecting access for patients with serious conditions where early adoption could be beneficial — though the waiver mechanism and post-year-3 FDA discretion preserve some flexibility.
• Pharmaceutical companies may shift marketing spend from direct-to-consumer channels to physician-targeted advertising and patient advocacy groups during the moratorium, potentially obscuring the source of promotional messaging.
• The bill's effectiveness depends on FDA regulatory capacity to monitor post-approval safety data and enforce advertising restrictions; underfunded implementation could render the protections nominal.
• International pharmaceutical firms may face asymmetric competitive pressure if other countries lack equivalent restrictions, potentially affecting U.S. drug pricing and market dynamics.

Who it affects

Ordinary citizens gain a cooling-off period before pharmaceutical companies can market new drugs directly to them, reducing pressure to demand untested medications and allowing time for post-approval safety data to accumulate. The FDA retains authority to restrict advertising of drugs with emerging safety signals, strengthening consumer protection.

Named in the bill

FDA (Food and Drug Administration), Pharmaceutical companies / drug sponsors, Social media platforms, Federal Food, Drug, and Cosmetic Act

Where it stands

• Feb 7, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 7, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 4 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $3,010,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Rosa DeLauro, the sponsor, reported $624,463 in PAC receipts in the 2026 cycle.

• America's Health Insurance Plans Inc (ahip) — $3,010,000 on 1 filing
• Coalition for Healthcare Communications — $0 on 3 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.